{"organizations": [], "uuid": "e482bf15441ab8e6d5e5454fced49350dcd01d99", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/29/business-wire-revance-announces-departure-of-chief-financial-officer.html", "country": "US", "domain_rank": 767, "title": "Revance Announces Departure of Chief Financial Officer", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.12, "site_type": "news", "published": "2018-05-29T15:00:00.000+03:00", "replies_count": 0, "uuid": "e482bf15441ab8e6d5e5454fced49350dcd01d99"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/29/business-wire-revance-announces-departure-of-chief-financial-officer.html", "ord_in_thread": 0, "title": "Revance Announces Departure of Chief Financial Officer", "locations": [], "entities": {"persons": [{"name": "silvernail", "sentiment": "none"}, {"name": "lauren silvernail", "sentiment": "none"}], "locations": [{"name": "newark", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "orange county", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "revance therapeutics, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "revance therapeutics", "sentiment": "none"}, {"name": "revance", "sentiment": "none"}, {"name": "revance therapeutics, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance’s Chief Financial Officer and Chief Business Officer, effective as of May 29, 2018, to pursue a Chief Financial Officer role at an aesthetics company in Orange County, California, where she resides. Her departure is not based on any disagreement with the company’s accounting principles or practices, internal controls or financial statement disclosures.\nFollowing Ms. Silvernail’s resignation, certain members of management and the Company’s existing finance team will assume the duties and responsibilities of the office on an interim basis.\nRevance is initiating a search for its next Chief Financial Officer, who will play an important role as the Company prepares for the commercialization of its lead product candidate, DaxibotulinumtoxinA for Injection (RT002).\nAbout Revance Therapeutics, Inc.\nRevance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com .\n\"Revance Therapeutics\" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180529005411/en/\nINVESTORS\nRevance Therapeutics, Inc.:\nJeanie Herbert, 714-325-3584\njherbert@revance.com\nor\nBurns McClellan, Inc.:\nAmi Bavishi, 212-213-0006\nabavishi@burnsmc.com\nor\nMEDIA\nGeneral Media:\nTOGORUN:\nMariann Caprino, 917-242-1087\nm.caprino@togorun.com\nor\nTrade Media:\nNadine Tosk, 504-453-8344\nnadinepr@gmail.com\nSource: Revance Therapeutics, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.revance.com&esheet=51813307&newsitemid=20180529005411&lan=en-US&anchor=www.revance.com&index=1&md5=83e05b411e025a260d80e304e4a6fc60", "https://www.businesswire.com/news/home/20180529005411/en/"], "published": "2018-05-29T15:00:00.000+03:00", "crawled": "2018-05-29T17:16:25.014+03:00", "highlightTitle": ""}